Although the majority of BRCA1-deficient cancer patients respond to DNA-damaging agents such as cisplatin and poly (ADP-ribose) polymerase (PARP) inhibitors, tumor recurrence and resistance, likely driven by TICs, combine to decrease the 5-year survival of such patients [23, 24]. Here, BRCA1 is linked to cancer.